Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05714969 · ClinicalTrials.gov registry record · Phase 2
A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)
A Phase 2 study of Thrombotic Thrombocytopenic Purpura (TTP), sponsored by Takeda.
- Active
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 20
- Study locations
NCT05714969 is a Phase 2 study of Thrombotic Thrombocytopenic Purpura (TTP) that is active but no longer recruiting, run by Takeda. The registered enrollment target is 33 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT05714969, a Phase 2 study of Thrombotic Thrombocytopenic Purpura (TTP), is active but no longer recruiting, sponsored by Takeda.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study of TAK-755 in adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP). The main aim of this study is to determine the percentage of participants with a clinical (Part 1) or platelet (Part 2) response without plasma exchange during the study. Participants who have an acute attack of iTTP will receive TAK-755 and immunosuppressive therapy during their stay at the hospital until they achieve a clinical response in Part 1 or platelet response in Part 2. Participants will also be treated with TAK-755 for an additional time of up to 6 weeks after the acute phase. In total, participants will stay in the study for approximately 3 months.
Conditions Studied
Interventions
- BIOLOGICAL TAK-755
Study Locations (20)
Other
- AKH - Medizinische Universitat Wien - Vienna
- General Hospital of Thessaloniki "G. Papanikolaou" - Thessaloniki
- Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico - Milan
- Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino - Torino
- Hospital General Universitario Gregorio Maranon - Madrid
- Hospital Universitari i Politecnic La Fe - Valencia
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
North Carolina
- Duke University Medical Center - Durham
- Leo Jenkins Cancer Center/ECU School of Medicine - Greenville
Florida
- University of Florida - Shands - Gainesville
Minnesota
- University of Minnesota Clinical Research Unit - Minneapolis
New Jersey
- Rutgers University - New Brunswick
New York
- Weill Cornell - New York
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2023-03-21 |
| Est. Completion | 2026-06-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05714969
The ClinicalTrials.gov registry entry for NCT05714969 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thrombotic Thrombocytopenic Purpura (TTP) appearing as the primary indexed condition, and to 1 intervention - of which TAK-755 is the first listed.
NCT05714969 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05714969 about?
NCT05714969 is a clinical study titled "A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)". This is a study of TAK-755 in adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP). The main aim of this study is to determine the percentage of participants with a clinical (Part 1) or platelet (Part 2) response without plasma exchange during the study. Participants who have an ac...
What is the current status of trial NCT05714969?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2023-03-21. Estimated completion is 2026-06-11.
What conditions does trial NCT05714969 study?
This clinical trial studies the following conditions: Thrombotic Thrombocytopenic Purpura (TTP).
What interventions are being tested in trial NCT05714969?
The interventions under investigation include: TAK-755 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05714969?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05714969 being conducted?
This trial has 20 study locations across Florida, Massachusetts, Minnesota, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombotic Thrombocytopenic Purpura (TTP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.